1 |
Abdulghani, J. and El-Deiry, W. S. 2010. TRAIL receptor signaling and therapeutics. Expert. Opin. Ther. Targets 14, 1091-1108.
DOI
|
2 |
Barneda-Zahonero, B. and Parra, M. 2012. Histone deacetylases and cancer. Mol. Oncol. 6, 579-589.
DOI
|
3 |
Benayoun, B., Baghdiguian, S., Lajmanovich, A., Bartoli, M., Daniele, N., Gicquel, E., Bourg, N., Raynaud, F., Pasquier, M. A., Suel, L., Lochmuller, H., Lefranc, G. and Richard, I. 2008. NF-kappaB-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A. FASEB J. 22, 1521-1529.
DOI
|
4 |
Billen, L. P., Shamas-Din, A. and Andrews, D. W. 2008. Bid: a Bax-like BH3 protein. Oncogene 27, S93-104.
DOI
|
5 |
Carew, J. S., Giles, F. J. and Nawrocki, S. T. 2008. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7-17.
DOI
|
6 |
Crowder, R. N. and El-Deiry, W. S. 2012. Caspase-8 regulation of TRAIL-mediated cell death. Exp. Oncol. 34, 160-164.
|
7 |
Donovan, M. and Cotter, T. G. 2004. Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. Biochim. Biophys. Acta 1644, 133-147.
DOI
|
8 |
Earel, J. K. Jr., VanOosten, R. L. and Griffith, T. S. 2006. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66, 499-507.
DOI
|
9 |
Fulda, S. 2012. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Exp. Cell Res. 318, 1208-1212.
DOI
|
10 |
Ghobrial, I. M., Witzig, T. E. and Adjei, A. A. 2005. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194.
DOI
|
11 |
Giménez-Bonafé, P., Tortosa, A. and Pérez-Tomás, R. 2009. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr. Cancer Drug Targets 9, 320-340.
DOI
|
12 |
Hussein, M. R., Haemel, A. K. and Wood, G. S. 2003. Apoptosis and melanoma: molecular mechanisms. J. Pathol. 199, 275-288.
DOI
|
13 |
Han, M. H., Park, C., Kwon, T. K., Kim, G. Y., Kim, W. J., Hong, S. H., Yoo, Y. H. and Choi, Y. H. 2015. The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL. Biomol. Ther. (Seoul) 23, 31-38.
DOI
|
14 |
Han, S. I., Kim, Y. S. and Kim, T. H. 2008. Role of apoptotic and necrotic cell death under physiologic conditions. BMB Rep. 41, 1-10.
DOI
|
15 |
Holcik, M., Gibson, H. and Korneluk, R. G. 2001. XIAP: apoptotic brake and promising therapeutic targe. Apoptosis 6, 253-261.
DOI
|
16 |
Inoue, H., Shiraki, K., Ohmori, S., Sakai, T., Deguchi, M., Yamanaka, T., Okano, H. and Nakano, T. 2002. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int. J. Mol. Med. 9, 521-525.
|
17 |
Jin, C. Y., Park, C., Cheong, J., Choi, B. T., Lee, T. H., Lee, J. D., Lee, W. H., Kim, G. Y., Ryu, C. H. and Choi, Y. H. 2007. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett. 257, 56-64.
DOI
|
18 |
Jin, C. Y., Park, C., Hong, S. H., Han, M. H., Jeong, J. W., Xu, H., Liu, H., Kim, G. Y., Kim, W. J., Yoo, Y. H. and Choi, Y. H. 2013. Synergistic induction of TRAIL-mediated apoptosis by anisomycin in human hepatoma cells via the BH3-only protein Bid and c-Jun/AP-1 signaling pathway. Biomed. Pharmacother. 67, 321-328.
DOI
|
19 |
Jin, C. Y., Park, C., Hwang, H. J., Kim, G. Y., Choi, B. T., Kim, W. J. and Choi, Y. H. 2011. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol. Nutr. Food Res. 55, 300-309.
DOI
|
20 |
Jin, Z. and El-Deiry, W. S. 2005. Overview of cell death signaling pathways. Cancer Biol. Ther. 4, 139-163.
|
21 |
Kantari, C. and Walczak, H. 2011. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim. Biophys. Acta 1813, 558-563.
DOI
|
22 |
Kelly, M. M., Hoel, B. D. and Voelkel-Johnson, C. 2002. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol. Ther. 1, 520-527.
DOI
|
23 |
Kim, E. Y., Ryu, J. H. and Kim, A. K. 2013. CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells. Int. J. Oncol. 43, 1291-1300.
DOI
|
24 |
Kim, Y. H., Park, J. W., Lee, J. Y. and Kwon, T. K. 2004. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25, 1813-1820.
DOI
|
25 |
Kouraklis, G. and Theocharis, S. 2002. Histone deacetylase inhibitors and anticancer therapy. Curr. Med. Chem. Anticancer Agents 2, 477-484.
DOI
|
26 |
Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G. and Earnshaw, W. C. 1994. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371, 346-347.
DOI
|
27 |
Lee, H. H., Jeong, J. W., Lee, J. H., Kim, G. Y., Cheong, J., Jeong, Y. K., Yoo, Y. H. and Choi, Y. H. 2013. Cordycepin increases sensitivity of Hep3B human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by inactivating the JNK signaling pathway. Oncol. Rep. 30, 1257-1264.
DOI
|
28 |
Mühlethaler-Mottet, A., Flahaut, M., Bourloud, K. B., Auderset, K., Meier, R., Joseph, J. M. and Gross, N. 2006. Histone deacetylase inhibitors strongly sensitise neuro-blastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 6, 214.
DOI
|
29 |
Mérino, D., Lalaoui, N., Morizot, A., Solary, E. and Micheau, O. 2007. TRAIL in cancer therapy: present and future challenges. Expert. Opin. Ther. Targets 11, 1299-1314.
DOI
|
30 |
Monneret, C. 2005. Histone deacetylase inhibitors. Eur. J. Med. Chem. 40, 1-13.
DOI
|
31 |
Park, C., Jin, C. Y., Hwang, H. J., Kim, G. Y., Jung, J. H., Kim, W. J., Yoo, Y. H. and Choi, Y. H. 2012. J7, a methyl jasmonate derivative, enhances TRAIL-mediated apoptosis through up-regulation of reactive oxygen species generation in human hepatoma HepG2 cells. Toxicol. In Vitro 26, 86-93.
DOI
|
32 |
Rae, C., Langa, S., Tucker, S. J. and MacEwan, D. J. 2007. Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc. Natl. Acad. Sci. USA 104, 12790-12795.
DOI
|
33 |
Rosato, R. R., Almenara, J. A., Dai, Y. and Grant, S. 2003. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2, 1273-1284.
|
34 |
Safa, A. R. and Pollok, K. E. 2011. Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers (Basel) 3, 1639-1671.
DOI
|
35 |
Teraishi, F., Kagawa, S., Watanabe, T., Tango, Y., Kawashima, T., Umeoka, T., Nisizaki, M., Tanaka, N. and Fujiwara, T. 2005. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett. 579, 4069-4075.
DOI
|
36 |
Seo, O. W., Kim, J. H., Lee, K. S., Lee, K. S., Kim, J. H., Won, M. H., Ha, K. S., Kwon, Y. G. and Kim, Y. M. 2012. Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells. Exp. Mol. Med. 44, 653-664.
DOI
|
37 |
Sonnemann, J., Gänge, J., Kumar, K. S., Müller, C., Bader, P. and Beck, J. F. 2005. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest. New Drugs 23, 99-109.
DOI
|
38 |
Srivastava, R. K. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3, 535-546.
DOI
|